Abstract
Abstract Consumers, when buying health insurance, do not know the exact value of each treatment that they buy coverage for. This leads them to overvalue some treatments and undervalue others. We show that the insurance market cannot correct these mistakes. This causes research labs to overinvest in treatments that hardly add value compared to current best practice. The government can stimulate R&D in breakthrough treatments by excluding treatments with low value added from health insurance coverage. If the country is rich enough such a government intervention in a private health insurance market raises welfare.
| Original language | English |
|---|---|
| Place of Publication | Tilburg |
| Publisher | TILEC |
| Number of pages | 40 |
| Volume | 2013-008 |
| Publication status | Published - 2013 |
Publication series
| Name | TILEC Discussion Paper |
|---|---|
| Volume | 2013-008 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 1 No Poverty
Keywords
- cost effectiveness analysis
- pharmaceutical research and development
- health insurance
Fingerprint
Dive into the research topics of 'Does the Market Choose Optimal Health Insurance Coverage'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver